NASDAQ:AMED Amedisys - AMED Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $73.55 +1.66 (+2.31%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$72.36▼$74.0050-Day Range$69.79▼$100.3352-Week Range$69.36▼$179.91Volume372,008 shsAverage Volume436,569 shsMarket Capitalization$2.39 billionP/E Ratio20.21Dividend YieldN/APrice Target$119.53 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Amedisys MarketRank™ ForecastAnalyst RatingHold2.36 Rating ScoreUpside/Downside62.5% Upside$119.53 Price TargetShort InterestHealthy5.65% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment0.42Based on 7 Articles This WeekInsider TradingSelling Shares$510,628 Sold Last QuarterProj. Earnings Growth10.33%From $4.26 to $4.70 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.05 out of 5 starsMedical Sector25th out of 1,004 stocksHome Health Care Services Industry3rd out of 9 stocks 4.2 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 7 buy ratings, 5 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $119.53, Amedisys has a forecasted upside of 62.5% from its current price of $73.55.Amount of Analyst CoverageAmedisys has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.65% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Amedisys has recently decreased by 13.88%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 2.5 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Amedisys this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for AMED on MarketBeat in the last 30 days. This is a decrease of -90% compared to the previous 30 days.MarketBeat Follows2 people have added Amedisys to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $510,628.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Amedisys is held by insiders.Percentage Held by Institutions96.17% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 10.33% in the coming year, from $4.26 to $4.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is 20.21, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is 20.21, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 108.48.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 2.04. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 2.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Amedisys (NASDAQ:AMED) StockAmedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.Read More Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address AMED Stock News HeadlinesMarch 31, 2023 | americanbankingnews.comAmedisys, Inc. (NASDAQ:AMED) Receives Average Rating of "Hold" from BrokeragesMarch 27, 2023 | finance.yahoo.comIs Amedisys, Inc. (NASDAQ:AMED) Potentially Undervalued?March 31, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 26, 2023 | marketwatch.comPost-Acute Long Term Care Market: Trends Shaping the Future 2023-2028March 26, 2023 | americanbankingnews.comAmedisys (NASDAQ:AMED) Stock Rating Upgraded by StockNews.comMarch 23, 2023 | finance.yahoo.comAmedisys Supports New Research that Demonstrates the Value of Hospice Care Through Better Outcomes and Medicare SavingsMarch 13, 2023 | finance.yahoo.comAmedisys Board Appoints Richard Ashworth as New President and Chief Executive OfficerMarch 13, 2023 | seekingalpha.comAmedisys names Richard Ashworth as new president and CEOMarch 31, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. March 13, 2023 | markets.businessinsider.comWhat 10 Analyst Ratings Have To Say About AmedisysMarch 9, 2023 | finance.yahoo.comAmedisys and nVoq Present Outcomes from Speech Recognition Study at PALTC23 ConferenceMarch 9, 2023 | finance.yahoo.comAmedisys to Present at Multiple Healthcare Conferences in MarchFebruary 16, 2023 | markets.businessinsider.comAmedisys Q4 Profit Decreases, but beats estimatesFebruary 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Seagen (SGEN)February 15, 2023 | finance.yahoo.comAmedisys (AMED) Surpasses Q4 Earnings and Revenue EstimatesFebruary 15, 2023 | finance.yahoo.comAmedisys Partners with BlueCross BlueShield of Tennessee to Provide Palliative Care at Home to MembersFebruary 15, 2023 | finance.yahoo.comAmedisys Reports Fourth Quarter and Year-End 2022 Financial Results, Issues 2023 Guidance, Announces Sale of Its Personal Care Line of Business and Signs Innovative Palliative Care at Home Partnership With BlueCross BlueShield of TennesseeFebruary 15, 2023 | finance.yahoo.comAmedisys Announces Divestiture of its Personal Care DivisionFebruary 9, 2023 | finance.yahoo.comAmedisys Board of Directors Authorizes $100 Million Stock Repurchase ProgramFebruary 8, 2023 | finance.yahoo.comAmedisys Honors 39 Employees With Annual Spirit Of Excellence AwardJanuary 30, 2023 | finance.yahoo.comAmedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call DatesJanuary 12, 2023 | finance.yahoo.comBe Wary Of Amedisys (NASDAQ:AMED) And Its Returns On CapitalDecember 28, 2022 | finance.yahoo.comAmedisys to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 23, 2022 | finance.yahoo.comComputerworld Names Amedisys to 2023 List of Best Places to Work in ITDecember 20, 2022 | finance.yahoo.comComputerworld Names Amedisys to 2023 List of Best Places to Work in ITDecember 13, 2022 | finance.yahoo.comAmedisys Completes Home Health Joint Venture with the University of Arkansas for Medical SciencesDecember 9, 2022 | finance.yahoo.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About Amedisys, Inc. (NASDAQ:AMED)?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address AMED Company Calendar Last Earnings2/16/2023Today3/31/2023Next Earnings (Estimated)4/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Home health care services Sub-IndustryHealth Care Services SectorMedical Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees20,000Year Founded1982Price Target and Rating Average Stock Price Forecast$119.53 High Stock Price Forecast$180.00 Low Stock Price Forecast$85.00 Forecasted Upside/Downside+62.5%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$3.64 Trailing P/E Ratio20.21 Forward P/E Ratio17.27 P/E Growth2.04Net Income$118.61 million Net Margins5.34% Pretax Margin7.21% Return on Equity15.44% Return on Assets8.31% Debt Debt-to-Equity Ratio0.38 Current Ratio1.09 Quick Ratio1.09 Sales & Book Value Annual Sales$2.22 billion Price / Sales1.08 Cash Flow$7.30 per share Price / Cash Flow10.08 Book Value$34.06 per share Price / Book2.16Miscellaneous Outstanding Shares32,550,000Free Float31,867,000Market Cap$2.39 billion OptionableOptionable Beta1.04 Social Links Key ExecutivesPaul B. K. KusserowChairman & Chief Executive OfficerScott G. GinnChief Operating & Financial Officer & EVPMichael P. NorthChief Information OfficerDenise M. BohnertChief Compliance OfficerKendra KimmonsVice President-Marketing & CommunicationsKey CompetitorsChemedNYSE:CHEAdaptHealthNASDAQ:AHCOAddus HomeCareNASDAQ:ADUSEnhabitNYSE:EHABOption Care HealthNASDAQ:OPCHView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 380 shares on 3/23/2023Ownership: 0.063%Michael Paul NorthSold 5,908 sharesTotal: $510,628.44 ($86.43/share)Voya Investment Management LLCSold 2,417 shares on 2/28/2023Ownership: 0.037%NatixisBought 11,000 shares on 2/24/2023Ownership: 0.034%Teachers Retirement System of The State of KentuckyBought 4,039 shares on 2/22/2023Ownership: 0.041%View All Insider TransactionsView All Institutional Transactions AMED Stock - Frequently Asked Questions Should I buy or sell Amedisys stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares. View AMED analyst ratings or view top-rated stocks. What is Amedisys' stock price forecast for 2023? 14 brokerages have issued 12 month price targets for Amedisys' stock. Their AMED share price forecasts range from $85.00 to $180.00. On average, they predict the company's share price to reach $119.53 in the next year. This suggests a possible upside of 62.5% from the stock's current price. View analysts price targets for AMED or view top-rated stocks among Wall Street analysts. How have AMED shares performed in 2023? Amedisys' stock was trading at $83.54 on January 1st, 2023. Since then, AMED shares have decreased by 12.0% and is now trading at $73.55. View the best growth stocks for 2023 here. Are investors shorting Amedisys? Amedisys saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 1,800,000 shares, a drop of 13.9% from the February 28th total of 2,090,000 shares. Based on an average trading volume of 436,400 shares, the days-to-cover ratio is presently 4.1 days. Currently, 5.7% of the company's stock are sold short. View Amedisys' Short Interest. When is Amedisys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023. View our AMED earnings forecast. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) announced its quarterly earnings data on Thursday, February, 16th. The health services provider reported $1.16 earnings per share for the quarter, topping analysts' consensus estimates of $1.03 by $0.13. The health services provider earned $562.10 million during the quarter, compared to analysts' expectations of $560.46 million. Amedisys had a net margin of 5.34% and a trailing twelve-month return on equity of 15.44%. The company's revenue for the quarter was up .5% on a year-over-year basis. During the same period last year, the company earned $1.18 EPS. What ETFs hold Amedisys' stock? ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include Simplify Health Care ETF (PINK), Harbor Health Care ETF (MEDI), SPDR S&P Health Care Services ETF (XHS), First Trust Health Care AlphaDEX Fund (FXH), SRH U.S. Quality ETF (SRHQ), Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD), iShares U.S. Healthcare Providers ETF (IHF) and Distillate Small/Mid Cash Flow ETF (DSMC). How will Amedisys' stock buyback program work? Amedisys announced that its Board of Directors has authorized a stock buyback plan on Wednesday, August 4th 2021, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 1.2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's management believes its stock is undervalued. What guidance has Amedisys issued on next quarter's earnings? Amedisys updated its FY23 earnings guidance on Wednesday, February, 15th. The company provided earnings per share guidance of $4.13-$4.36 for the period, compared to the consensus estimate of $4.88. The company issued revenue guidance of $2.244-$2.274 billion, compared to the consensus revenue estimate of $2.36 billion. What is Paul B. Kusserow's approval rating as Amedisys' CEO? 478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD). What is Amedisys' stock symbol? Amedisys trades on the NASDAQ under the ticker symbol "AMED." Who are Amedisys' major shareholders? Amedisys' stock is owned by many different institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (5.42%), Riverbridge Partners LLC (4.70%), Mackenzie Financial Corp (3.20%), Point72 Asset Management L.P. (1.70%), Credit Suisse AG (1.64%) and Millennium Management LLC (1.47%). Insiders that own company stock include Bruce D Perkins, Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Julie D Klapstein, Michael Paul North, Richard A Lechleiter, Scott G Ginn and Sharon Brunecz. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Amedisys' stock price today? One share of AMED stock can currently be purchased for approximately $73.55. How much money does Amedisys make? Amedisys (NASDAQ:AMED) has a market capitalization of $2.39 billion and generates $2.22 billion in revenue each year. The health services provider earns $118.61 million in net income (profit) each year or $3.64 on an earnings per share basis. How many employees does Amedisys have? The company employs 20,000 workers across the globe. How can I contact Amedisys? Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The official website for the company is www.amedisys.com. The health services provider can be reached via phone at (225) 292-2031, via email at ir@amedisys.com, or via fax at 225-292-8163. This page (NASDAQ:AMED) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.